Behind The Knife: The Surgery Podcast cover image

Journal Review in Breast Surgery: Evolution of DCIS Management

Behind The Knife: The Surgery Podcast

00:00

The Effects of Pembrolizumabylon on the Immune System

Dr. Riven: DCIs are just as heterogeneous as invasive cancer. We don't treat all breast cancers the same. And there are some cancers that are super low risk that don't need much therapy at all either. The reason why they're still DCS is because they have this immune infiltrate.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app